Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 3

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 142Leukemia 41Leukemia, Myeloid, Chronic-Phase 35Blast Crisis 17Philadelphia Chromosome 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Leukemia, Myeloid, Accelerated Phase 10Leukemia, Myeloid 9Primary Myelofibrosis 7Leukemia, Myelomonocytic, Chronic 7Leukemia, Myeloid, Acute 7Polycythemia Vera 6Myeloproliferative Disorders 6Hypereosinophilic Syndrome 5Hematologic Neoplasms 5Hematologic Diseases 5Bone Marrow Diseases 5Multiple Myeloma 4Gastrointestinal Stromal Tumors 4Thrombocythemia, Essential 3Myelodysplastic Syndromes 3Mastocytosis 3Leukemia, Lymphocytic, Chronic, B-Cell 3Bronchiolitis Obliterans Syndrome 3Recurrence 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Neoplasms by Histologic Type 2Neoplasms 2Neoplasm, Residual 2Mastocytosis, Systemic 2

Interventions

nilotinib 3asciminib 3Imatinib Mesylate 3bosutinib 2Dasatinib 2ruxolitinib 1ponatinib 1milatuzumab 1lonafarnib 1Vision, Ocular 1Panobinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Bronchiolitis Obliterans Syndrome × Imatinib Mesylate × Myeloid × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00802841 2015-11-16

LASOR

Novartis

Phase 3 Completed
191 enrolled 13 charts
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01819389 2014-01-07

Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance

Hospital Universitario Dr. Jose E. Gonzalez

Phase 3 Completed
10 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡